Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Axcellant, a boutique CRO, seeks an ambitious Business Development Manager to drive new business generation and build lasting sponsor relationships across Europe with selective global reach. You will own the full BD lifecycle, collaborating with senior leadership to shape proposals, defend bids, and close complex deals.
You will engage with Clinical Operations, Development, Outsourcing, and Scientific Leadership, translating capabilities into compelling value propositions and contributing to
Axcellant is a boutique Clinical Research Organization supporting pharma, biotech, and innovative sponsors in the execution of complex, high-impact clinical trials—including oncology, rare diseases, radiopharmaceuticals, advanced diagnostics, and other demanding study designs.
We combine senior-level involvement, operational agility, and scientific depth with a pragmatic, partner-driven approach. As we scale our commercial footprint in Europe and beyond, we are looking for a Business Development Manager who can help shape our growth trajectory—not just execute a sales plan.
This role is ideal for someone who thrives in lean, high-ownership environments, understands how sponsors buy CRO services, and is motivated by building something meaningful rather than selling at scale.
As Business Development Manager, you will be responsible for driving new business generation, building long-term sponsor relationships, and positioning Axcellant as a trusted CRO partner for complex clinical programs.
You will own the full business development lifecycle—from opportunity identification and early engagement through proposal development, bid defence, and contract award—working closely with Axcellant’s senior leadership and operational experts.
This is a hands-on, high-impact role with direct visibility and influence on company strategy.
Experience in areas such as oncology, rare diseases, imaging, nuclear medicine, advanced diagnostics, or complex trial designs will be considered an advantage—but mindset and capability matter more than labels.